AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab
AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Regeneron to market with a bispecific antibody that could contest with CAR-T therapies.
Genmab has always targeted a mid-2020 deal, including the rights to CD3xCD20 bispecific antibody epcoritamab.
Now, AbbVie has landed rights to epcoritamab by approving to Genmab’s redlines for the agreement, putting up USD 750 million upfront and committing to a ...
